BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers
Open Access
- 18 June 2021
- Vol. 9 (6), 672
- https://doi.org/10.3390/vaccines9060672
Abstract
The BNT162b2 vaccine, containing lipid nanoparticles-formulated mRNA encoding the full-length spike protein of SARS-CoV-2, has been employed to immunize health care workers in Italy, administered in two doses 21 days apart. In this study, we characterized the antibody response induced by the BNT162b2 vaccine in a group of health care workers, tested at baseline, after the first dose and after the booster. Thirty-nine subjects without previous exposure to SARS-CoV-2 were vaccinated with the BNT162b2 vaccine. IgM, IgG, and IgA anti-receptor binding domain (RBD) were tested by ELISA. Neutralizing antibodies were evaluated testing the inhibition of RBD binding to ACE2. Antibody avidity was measured by urea avidity ELISA. IgM anti-RBD are produced after the first dose of vaccine and persist after the booster. IgG and IgA anti-RBD antibodies are detected in high amounts in all the subjects after the first dose and further increase after the booster. A few subjects, already after the first dose, produce antibodies inhibiting RBD interaction with ACE2. After the booster, high levels of inhibitory antibodies are detected in all the subjects. Affinity maturation takes place with boosting and IgG anti-RBD avidity increases with the number of immunizations. A less pronounced increase is observed with IgA. These data indicate that the BNT162b2 vaccine can induce high levels of protective antibodies of high avidity in vaccinated subjects; both IgG and IgA anti-RBD antibodies are produced. Further studies are needed to evaluate antibody persistence over time.Funding Information
- Ministero della Salute (COVID-2020-12371849)
This publication has 32 references indexed in Scilit:
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma DonorsThe Journal of Infectious Diseases, 2020
- Immunological considerations for COVID-19 vaccine strategiesNature Reviews Immunology, 2020
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020
- Use of the immunoglobulin G avidity assay to differentiate between recent Zika and past dengue virus infectionsClinical Science, 2019
- Comparison of different enzyme‐linked immunosorbent assay methods for avidity determination of antiphospholipid antibodiesJournal of Clinical Laboratory Analysis, 2017
- Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsMolecular and Cellular Probes, 2012
- Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA)Journal of Immunological Methods, 1997
- Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virusJournal of Clinical Laboratory Analysis, 1994